India is not relaxing pharma compliance. It is changing the punishment architecture for selected minor and procedural lapses.
The Jan Vishwas reforms are positioned as a trust-based governance move. The idea is to reduce unnecessary criminalisation, simplify enforcement, and create a more business-friendly regulatory environment.
But for pharma, this should not be misunderstood.
This is not a free pass.
It is not a dilution of GMP.
It is not a relaxation of product quality, patient safety, data integrity, or manufacturing discipline.
Instead, it separates minor procedural non-compliances from serious public health offences.
1. This is not blanket relief for pharma manufacturers
For pharma companies, the most relevant change is around procedural and documentation-related compliance.
Section 28A of the Drugs and Cosmetics Act deals with failure to maintain records, documents, registers, or furnish required information under Section 18B.
Earlier, such violations could attract imprisonment up to one year, a fine, or both.
Under the Jan Vishwas changes, this is converted into an administrative penalty framework, with penalties ranging from ₹3 lakh to ₹5 lakh.
This reduces criminal anxiety for genuine procedural lapses.
But it does not reduce the seriousness of record-keeping.
In fact, it may speed up enforcement.
A criminal case takes time. An administrative penalty can move much faster.
So for pharma companies, the risk shifts from:
“Will this become a criminal case?”
to
“Can we prove compliance quickly when asked?”
2. Documentation becomes more important, not less
The biggest mistake companies can make is to think:
“Decriminalised means less serious.”
That would be dangerous.
The revised framework may reduce criminal prosecution for selected procedural gaps, but the expectation of documentation control remains high.
For pharma companies, this means stronger control over:
- Batch records
- SOPs
- Specs, STPs
- Registers
- Licences
- Test reports
- Validation records
- Change controls
- Training records
- Complaints and recalls
- Inspection responses
- Information submitted to regulators
If these records are scattered, outdated, manual, or difficult to retrieve, the company may still face regulatory action.
The difference is that action may now come through a faster administrative penalty route.
3. Cosmetic compliance gets a more practical distinction
The reforms also affect cosmetics.
Certain low-risk cosmetic violations, such as minor quality parameter failures or labelling deficiencies, are now brought under an administrative penalty framework.
Not every cosmetic non-compliance should be treated like a serious public health offence.
But the government has clearly retained strict penal provisions for spurious and adulterated cosmetics.
This distinction is important.
Minor labelling or technical errors may be handled more proportionately.
But anything affecting consumer safety remains serious.
4. Omission of Section 29 is useful, but not a marketing free pass
Section 29 of the Drugs and Cosmetics Act, which dealt with use of a Government Analyst’s report for advertising a drug or cosmetic, has been omitted.
This reduces an older, narrow compliance restriction.
But companies should not treat this as permission for aggressive or unsupported marketing claims.
Pharma and cosmetic communication will still be governed by other laws, product approvals, labelling norms, restrictions on drug advertising, consumer protection principles, and regulatory expectations.
For marketing and regulatory teams, the message is simple:
Claim discipline still matters.
Every claim should be approved, substantiated, traceable, and aligned with the product’s permitted use.
5. Administrative adjudication will make enforcement faster
One of the most important changes is the introduction of adjudicating authorities and appeal mechanisms. Under the new structure, authorised officers can inquire into specified contraventions and impose penalties.
Appeals must be filed within a defined timeline and are expected to be disposed of within a defined period.
If the penalty is not paid, it can be recovered as arrears of land revenue.
This makes the system more direct.
Earlier, prosecution-based enforcement could be slow and complex.
Now, selected contraventions may be handled through a more administrative, time-bound route.
For companies, this means they must be ready with:
- Clear documentation
- Internal investigation records
- Corrective action history
- Justification notes
- Regulatory correspondence
- Audit trails
- Proof of timely compliance
6. Penalties will keep increasing
Another important point is that fines and penalties under scheduled laws may increase by 10% of the minimum amount every three years, unless the respective law provides its own revision mechanism.
This means compliance costs will not remain static.
For multi-site pharma companies, MSMEs, loan licence manufacturers, contract manufacturers, and exporters, this can become significant over time.
The cost of weak documentation may rise every few years.
What This Means for Indian Pharma
For well-run pharma companies, this reform is positive.
It reduces fear of criminal prosecution for selected procedural lapses and supports ease of doing business.
But for companies with weak systems, this is a warning.
Because administrative penalties can be easier and faster to impose than criminal prosecution.
Jan Vishwas does not reduce the need for compliance.
It changes the way non-compliance will be handled.
For Indian pharma, the response needs to be a stronger digital compliance infrastructure.